Osteogenesis Imperfecta
Conditions
Brief summary
Osteogenesis imperfecta (OI) is a group of congenital and heritable bone disorders that currently affects at least 50,000 people in the United States. OI varies in severity from perinatally lethal to mild forms. The majority of cases is caused by a dominant mutation in type I collagen genes (COL1α1 and COL1α2), altering the quantity or quality of type I collagen. Although OI is typically characterized as a disease of the bone, it is perhaps more accurately described as a connective tissue disorder. Type I collagen is a major constituent of lung connective tissue. Respiratory insufficiency is the leading cause of death in patients with OI. Thus, it is important and necessary to understand the etiology of the restrictive pulmonary physiology in the OI population.
Detailed description
This study is cross-sectional. At the participant's one study visit, data will be obtained at a single point in time and reflect the patients' current condition. Evaluations will include family and medical history, self-report questionnaires, physical evaluation, diagnostic studies, and radiographic studies. Eighteen participants will be enrolled, ideally within one year. Participants will be enrolled regardless of OI type since Bronchial Wall Thickening, a finding we are attempting to validate, was observed in all types of OI. Interested males with OI will be preferred over females to compensate for our highly female original cohort and determine if sexual dimorphism exists for cardiopulmonary outcomes in people with OI. Smokers will not be excluded.
Interventions
None listed
Sponsors
Baylor College of Medicine
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Individuals who are able to give informed consent or have a legally authorized representative capable of giving consent on the subject's behalf * Individuals ages 18 and older of all races and sexes * Individuals who have been diagnosed with OI clinically and/or genetically
Exclusion criteria
* Individuals diagnosed with respiratory illness within 6 weeks of enrollment or undergoing diagnostic studies for an active illness. * Individuals with other skeletal dysplasia or genetic diagnosis * Individuals diagnosed with cardiopulmonary comorbidities that affect lung compliance
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| proportion of restrictive lung physiology | 12 months | FEV1/FVC greater than or equal to 80%, which is obtained from PFT |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Presence and severity of Bronchial Wall Thickening | 12 months | measurement of percent of bronchial diameter subsumed by wall thickness |
| Vital lung capacity | 12 months | Vital capacity/total lung capacity/chest volume prediction based on 1) readings by trained chest CT readers and 2) 3-D lung imaging calculation |
| Presences of pulmonary fibrosis | 12 months | Presence of pulmonary fibrosis based on readings by trained chest CT readers |
| Change in lung tissue | 12 months | location of bronchiectasis, and presence of atelectasis based on readings by trained chest CT readers |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORVernon Sutton, MD
Baylor College of Medicine
STUDY_CHAIRKathleen Raggio
Hospital for Special Surgery, New York
Outcome results
None listed